IO102-IO103
1 product
17 abstracts
Abstract
A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.Org: Institute Gustave Roussy and Paris Saclay University, Dermatology Department Hospital Center University De Lille, Department of Dermatology Comprehensive Cancer Center, Westdeutsches Tumorzentrum University Hospital Essen & Research Alliance Ruhr & Research Center One Health University Duisburg-Essen, Department of Medical Oncology Dana-Farber Cancer Institute,
Abstract
Efficacy of immunotherapy retreatment in patients with non-small cell lung cancer receiving consolidative durvalumab.Org: The University of North Carolina Medical Center,
Abstract
A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma.Org: Lehigh Valley Topper Cancer Institute,
Abstract
A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).Org: Translational Research in Oncology, Canada,
Abstract
Impact of CTNNB1 alterations on outcomes in patients with hepatocellular carcinoma (HCC).Org: Caris Life Sciences, Irving, TX, Mayo Clinic Scottsdale,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: NRG Oncology Statistics and Data Management Center, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, University Hospitals Seidman Cancer Center, Cleveland, OH, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Radiology School of Medicine, University of California, San Francisco, San Francisco, CA,
Abstract
Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.Org: Oncology Associates of Oregon P.C., Maryland Oncology Hematology, Illinois Cancer Specialists, Southern Cancer Center, Woodlands Medical Specialists,
Abstract
Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing.Org: Vindhya Data Science, Durham Veteran Affairs Medical Center, NC Medical Research, Vanderbilt University Medical Center, Nashville,
Abstract
Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma.Org: Department of Experimental, Diagnostic, and Specialty Medicine, S.Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy, Vall d'Hebron University Hospital, Barcelona, Spain, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, Bologna, Italy, Medical Oncology Unit, Macerata General Hospital, Macerata, Italy, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy, Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,
Abstract
Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Org: Huntsman Cancer Institute at the University of Utah, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, BC Cancer Agency Vancouver Island Centre, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada,
Abstract
Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the National Cancer Database (NCDB).Org: SUNY Upstate Medical University, Department of Public Health & Preventive Medicine, College of Medicine, University of the Philippines - Manila, SUNY Upstate University Hospital,
Abstract
Assessment of sociodemographic disparities in outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE.Org: Georgetown University Medical School, AstraZeneca, Centre Hospitalier Universitaire Vaudois (CHUV),
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
Clinical outcomes with frontline immunotherapy (IO) in BRAF-mutant NSCLC.Org: Indiana University – Purdue University Indianapolis, Moffitt Cancer Center, Huntsman Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Weight loss (WL) as a predictive factor for immune oncology (IO).Org: University of Arkansas for Medical Sciences (UAMS), UAMS Clinical Practice,
Abstract
Clinical efficacy of frontline immunotherapy (IO) in ethnic-minority patients (pts) with metastatic NSCLC.Org: Montefiore-Einstein Cancer Center, Albert Einstein College of Medicine, Montefiore Einstein Center for Cancer Care, Montefiore Medical Center, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy.Org: Advicenne Pharma, Canopy Growth, Highlands Oncology Group, Northwest Medical Specialties, CSNF,